Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

Poxel (Group)

Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel’s first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin’s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. *

 

Period Start 2009-03-11 splitoff
  Predecessor Merck Serono (division of Merck KGaA)
Products Industry imeglimin
  Industry 2 PXL770 (Poxel)
Persons Person Kuhn, Thomas (Poxel 200904– CEO)
  Person 2 Malgouyres, Pascale (Poxel 200904– Business Development Director)
     
Region Region Lyon
  Country France
     
Basic data Employees B: 11 to 50 (2014-11-08)
  Currency EUR
  Cash 42,400,000 (2015-12-31)
     
    * Document for �About Section�: Poxel S.A.. (11/5/19). "Press Release: Poxel Obtains Additional Funding to Advance Pipeline Programs. Financing of up to EUR 30 Million through a Bond Loan with IPF Partners". Lyon.
     
   
Record changed: 2019-11-07

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Poxel (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px




» top